Halozyme Therapeutics

Yahoo Finance • 12 days ago

Where is Halozyme Therapeutics (HALO) Headed According to Analysts?

Halozyme Therapeutics, Inc. (NASDAQ:HALO) is one of the best affordable biotech stocks to invest in now. On August 18, Morgan Stanley raised the firm’s price target on Halozyme Therapeutics, Inc. (NASDAQ:HALO) to $80 from $75, keeping an O... Full story

Yahoo Finance • 15 days ago

Halozyme Therapeutics Inc (NASDAQ:HALO) Presents a Compelling Case for Value Investors

In value investing, the search for undervalued stocks with strong basic foundations remains a central strategy. This approach, started by Benjamin Graham and later improved by investors like Warren Buffett, focuses on finding companies tra... Full story

Yahoo Finance • 21 days ago

Halozyme Therapeutics Inc (NASDAQ:HALO) Fits Minervini's Trend Template with Strong Technicals and Earnings Momentum

The method used to find good investment chances joins Mark Minervini’s strict Trend Template with a concentration on strong-growth momentum. Minervini’s method highlights stocks showing solid technical condition, characterized by upward-mo... Full story

Yahoo Finance • 25 days ago

HALOZYME THERAPEUTICS INC (NASDAQ:HALO) Offers Affordable Growth With Strong Fundamentals

Investors seeking growth opportunities at reasonable valuations often turn to strategies that balance expansion potential with financial prudence. The "Affordable Growth" approach specifically targets companies demonstrating solid growth p... Full story

Yahoo Finance • last month

KalVista Pharmaceuticals Stock Sees RS Rating Rise To 82

On Wednesday, KalVista Pharmaceuticals stock reached an important technical milestone, seeing its Relative Strength (RS) Rating jump into the 80-plus percentile with an improvement to 82, up from 79 the day before. Is KalVista Pharmaceutic... Full story

Yahoo Finance • last month

HALOZYME THERAPEUTICS INC (NASDAQ:HALO) Stands Out in Navellier's Growth Screen

In growth investing, few strategies have received as much notice as the one described in Louis Navellier’s 2007 book, _The Little Book That Makes You Rich_. The approach focuses on finding companies showing solid, quickening growth through... Full story

Yahoo Finance • last month

Halozyme Therapeutics (HALO) Fell Despite Reporting Strong Earnings and Improved Guidance

Artisan Partners, an investment management company, released its “Artisan Small Cap Fund” second-quarter 2025 investor letter. A copy of the letter can be downloaded here. Global markets saw an incredible but volatile second quarter, shift... Full story

Yahoo Finance • last month

Health care stocks with the largest net increases in hedge fund popularity – Goldman Sachs

[Medical industry stock market graph chart] Rasi Bhadramani Hedge funds increased their overweight positioning in health care (NYSEARCA:XLV [https://seekingalpha.com/symbol/XLV]) despite a 7% decline in the sector during the second quarte... Full story

Yahoo Finance • last month

Halozyme Therapeutics stock reaches all-time high at 70.57 USD

Halozyme Therapeutics (NASDAQ:HALO) Inc. stock has reached an all-time high, hitting 70.57 USD. The milestone caps an impressive year-to-date gain of 44.24%, significantly outperforming its 15.48% one-year return. According to InvestingPr... Full story

Yahoo Finance • last month

HALOZYME THERAPEUTICS INC (NASDAQ:HALO) – A Top Pick for Affordable Growth Investors

Investors looking for growth opportunities at fair prices often consider the "Affordable Growth" strategy, which finds stocks with solid growth potential while keeping strong financial health and profitability, all at a valuation that does... Full story

Yahoo Finance • 2 months ago

Halozyme’s CEO Helen Torley sells $3.8m in shares

Helen Torley, President and CEO of Halozyme Therapeutics, INC. (NASDAQ:HALO), a $7.6 billion biotechnology company with an "EXCELLENT" financial health rating according to InvestingPro, sold a total of 59,850 shares of common stock between... Full story

Yahoo Finance • 2 months ago

H.C. Wainwright Lifts PT on Halozyme Therapeutics (HALO) to $75 From $72

Halozyme Therapeutics, Inc. (NASDAQ:HALO) is one of the top most undervalued biotech stocks to buy now. On August 6, H.C. Wainwright analyst Mitchell Kapoor raised the firm’s price target on Halozyme Therapeutics, Inc. (NASDAQ:HALO) to $75... Full story

Yahoo Finance • 2 months ago

Here’s Why Halozyme Therapeutics (HALO) Traded Town in Q2

Meridian Funds, managed by ArrowMark Partners, released its “Meridian Growth Fund” second-quarter 2025 investor letter. A copy of the letter can be downloaded here. U.S. equity markets made a significant rebound during the quarter, increas... Full story

Yahoo Finance • 2 months ago

Halozyme Therapeutics Guidance Upgrade Driven by Robust Royalty Revenue, Morgan Stanley Says

Halozyme Therapeutics (HALO) fiscal 2025 guidance update following Q2 revenue beat driven by royalty PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 2 months ago

HALOZYME THERAPEUTICS INC (NASDAQ:HALO) Fits Louis Navellier’s High-Growth Stock Criteria

Louis Navellier’s _The Little Book That Makes You Rich_ presents a structured method for finding high-growth stocks using eight key factors. These rules examine earnings updates, sales and profit increases, wider operating margins, solid c... Full story

Yahoo Finance • 2 months ago

Halozyme raises 2025 revenue guidance to $1.355B amid accelerating royalty growth and new product catalysts

Earnings Call Insights: Halozyme Therapeutics (HALO) Q2 2025 MANAGEMENT VIEW * CEO Helen I. Torley opened the call stating, "I'm pleased to announce another record quarter, which highlights the significant growth and accelerating momen... Full story

Yahoo Finance • 2 months ago

Halozyme Therapeutics gains as Q2 earnings crush estimates

Investing.com -- Halozyme Therapeutics Inc (NASDAQ:HALO) shares surged 5.3% after the company reported second-quarter earnings that significantly exceeded analyst expectations and raised its full-year guidance for the second time this ye... Full story

Yahoo Finance • 2 months ago

HALOZYME THERAPEUTICS INC (NASDAQ:HALO) Shows Strong Growth Momentum and Technical Breakout Potential

Investors looking for high-growth momentum stocks with strong technical setups often focus on companies showing faster earnings growth, wider profit margins, and rising analyst estimates, all while displaying positive chart patterns. The C... Full story

Yahoo Finance • 2 months ago

Halozyme Therapeutics Inc (NASDAQ:HALO) Stands Out as a Strong Undervalued Stock with Solid Fundamentals

Halozyme Therapeutics Inc (NASDAQ:HALO [https://www.chartmill.com/stock/quote/HALO]) has been recognized through a fundamental screening method aimed at finding undervalued stocks with solid financial strength. The "Decent Value" screen se... Full story

Yahoo Finance • 2 months ago

J&J says Darzalex injectable granted EU nod for smouldering multiple myeloma

[Johnson & Johnson offices in Silicon Valley] Sundry Photography/iStock Editorial via Getty Images Johnson & Johnson (NYSE:JNJ [https://seekingalpha.com/symbol/JNJ]) announced on Wednesday that the European Commission approved an injectab... Full story